Protocol Ledger

NCT03881696 · Phase III · COMPLETED

Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants

Interventional Phase III clinical trial protocol NCT03881696 sponsored by National Institute of Allergy and Infectious Diseases (NIAID) in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-07-22 Enrollment: 458 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03881696
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)458 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03881696
Protocol FieldVerified Registry Value
NCT IdentifierNCT03881696
Consolidated Lead SponsorNational Institute of Allergy and Infectious Diseases (NIAID)
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment458 participants (ACTUAL)
Registered Start Date2019-07-22
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI